Solara Pharma Receives ₹161.92 Crore Tax Demand Notice for AY 2019-20
Solara Active Pharma Sciences Limited received a tax demand notice of ₹161.92 Crores for Assessment Year 2019-20 due to disallowed expenses. The company plans to appeal the order, stating it does not expect a material financial impact.
While the company states no material financial impact is expected, a tax demand of ₹161.92 Crores could potentially impact liquidity and operations if the appeal is unsuccessful.
The company has received a significant tax demand notice, which is generally a negative development.
Solara Active Pharma Sciences Limited has received a Notice of Demand under Section 156 of the Income Tax Act, 1961, from the Deputy Commissioner of Income Tax, Central Circle-3, Thane. This notice pertains to the assessment year 2019-20 and follows the disallowance of certain expenses claimed by the company in its Income Tax Return.
The total tax demand amounts to ₹161.92 Crores. The company received this communication on March 17, 2026.
Solara Active Pharma Sciences Limited stated that it believes it has merits in the case and does not expect any material impact on the company financially or otherwise. The company is preparing to file an appeal against this order before the concerned Appellate Authority within the prescribed timelines.
What to do with a filing like this
Solara Active Pharma Sciences Limited filed this with the NSE as a statutory disclosure, categorised under taxation. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Solara Active Pharma Sciences Limited. Read the original for the full detail.